<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vascular endothelial growth factor (VEGF) seems to play a central role in <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>-lymphangiogenesis in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>There are limited data related to childhood <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of the study was to evaluate soluble VEGF (sVEGF) levels in children with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> and malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (ML) at diagnosis and in remission </plain></SENT>
<SENT sid="3" pm="."><plain>The levels of serum sVEGF were measured by enzyme-linked immunosorbent assay (ELISA) in 20 children with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, 33 children with different histopathological subtypes of ML, and 20 healthy controls </plain></SENT>
<SENT sid="4" pm="."><plain>The levels of sVEGF at diagnosis (range 2 -1040 pg/mL; median 52 pg/mL) was significantly lower than in remission (range 136 -1960 pg/mL; median 630 pg/mL) in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) group (P = .018) </plain></SENT>
<SENT sid="5" pm="."><plain>The sVEGF levels at diagnosis (range: 2 -640 pg/mL; median 89 pg/mL) was significantly lower compared to remission values (range: 116 -1960 pg/mL; median 136 pg/mL) in patients with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) (P = .002) </plain></SENT>
<SENT sid="6" pm="."><plain>In ML group, including Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), T-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), and Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>), sVEGF levels at diagnosis were higher than remission levels, but there was no statistically significant difference (P &gt;.05) </plain></SENT>
<SENT sid="7" pm="."><plain>On the other hand, there were significant difference between levels in active disease and control group, ie, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> versus control, T-cell NHL versus control, and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> versus control (P = .008, P = .043, P = .007, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>The authors noticed that sVEGF levels showed distinct behavioral pattern in different childhood <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> at diagnosis and in remission </plain></SENT>
<SENT sid="9" pm="."><plain>In <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> and ML patients, VEGF acts through different pathophysiological mechanisms, in both bone marrow (BM) <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and lymphoid tissue lymphangiogenesis </plain></SENT>
</text></document>